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Epithelial Ovarian Cancer: Treatment Has Improved,
But Not Enough
byDavidM. Gershenson, M.D.
Department of Gynecowgy
With an estimated 19,000
new cases in 1987, ovarian
cancer is now the second most
common malignant disease of
the genital tract of women in
this country. About 1.4% or
one of every 70 newborn girls
will develop ovarian cancer
during her lifetime. According
to the American Cancer SocieDavid M. Gershenson
ty's estimate, 11,700 women
died as a result of ovarian cancer last year.
Epithelial ovarian cancer, the most common type, accounts for 85% of ovarian malignant tumors. Unfortunately, by the time it is diagnosed, about 75% of patients
already have advanced disease with ascites and metastases
in the upper abdomen.

antibody that was raised against an epithelial ovarian cancer
cell line and that binds to its antigen. A CA-125 marker is
currently being used to monitor response in ovarian cancer
patients undergoing therapy and to diagnose recurrence in
patients after completion of therapy; it is also being studied as an alternative to second-look laparotomy. Unfortunately, CA-125 is not specific to epithelial ovarian cancer;
it can be elevated in early pregnancy and a variety of benign
diseases, including liver disease, acute pancreatitis, peritonitis, renal failure, endometriosis, and pelvic inflammatory
disease. Furthermore, elevated CA-125 levels have been
noted in other gynecologic cancers such as adenocarcinomas of the endometrium, endocervix, and fallopian tube,

Identify Tumor Markers
Although much valuable research has been done in the
last two decades to identify tumor markers for this cancer,
the ideal tumor marker is far from a reality. The potential
benefits of having such a marker include the ability to detect the disease early in its course and to distinguish benign
from malignant tumors before operations, to distinguish
ovarian cancer from other cancers that have similar manifestations, monitor patients' response during therapy and
the maintenance of remission afterward, and possibly to
replace second-look laparotomy in the standard management of this disease.
So far, the most promising serum tumor marker for epithelial ovarian cancer is CA-125, a murine monoclonal

A Report to \::.

as well as nongynecologic cancers of the pancreas, colon,
breast, and lung. Ultimately, ovarian cancer will probably
be detected with a panel of two or more monoclonal antibodies rather than a single one. Then, after a reliable preoperative diagnosis, patients who have the disease could be
referred to gynecologic oncologists trained in aggressive
cytoreductive surgical techniques.
continued on page 2
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ease is apparently confined to one ovary; this is so especially
for patients with borderline or other low-grade tumors. But
even if a patient has bilateral tumors , hysterectomy is not
always necessary. Preserving the uterus of a young patient
undergoing bilateral salpingo-oophorectomy may enable
the patient to undergo in vitro fertili zation with donor
oocytes, if she and her family so desire.

Surgical Intervention Still Most Important
Surgery remains the cornerstone of epithelial ovarian
cancer management. Primary surgical intervention enables
physicians to confirm the diagnosis; determine the extent
of disease precisely-that is, stage it-and perform maximum cytoreductive surgery in patients with advanced
disease.
A meticulous, methodical approach is particularly critical
for detecting occult or microscopic metastasis in patients
with apparent early disease. Proper staging procedures
include an adequate vertical midline incision, cytologic
analysis of ascites or cytologic washings of the pelvis and
bilateral paracolic gutters, and thorough inspection and
palpation of all intraperitoneal contents. In addition to
resection of the primary tumors, if the disease seems to be
confined to one or both ovaries, the structures at riskincluding the omen tum and peritoneal surfaces of the pelvis and upper abdomen and the paraaortic and bilateral
pelvic lymph-node-bearing areas-should be examined by
random staging biopsies. Lymph nodes are involved more
commonly in epithelial tumors than was previously thought,
and several reports have documented occult metastasis in
apparent stages I and II disease. Of all patients with so-

Postoperative Radiotherapy
Postoperative treatment in patients with epithelial ovarian cancer may be done with radioisotopes, external radiotherapy, and chemotherapy. The radiotherapy studies
reported in the literature suffer from the same sorts of
problems that plagued many early studies of ovarian cancer
patients-poor study design, inadequate surgical staging,
lack of uniform histologic analysis, and not the best statistical methods. Nevertheless, current evidence suggests that
radiotherapy, if it has any role in pri mary postoperative
therapy, is effective only in patients with minimal residual
disease.
Interest in radiotherapy as part of multimodality treatment has grown recently, with abdominopelvic irradiation
administered to patients who were found to have minimal
persistent disease at second-look laparotomy, after primary
cytoreductive surgery and combination chemotherapy.
Preliminary results of these studies suggested, however,
that these patients found radiotherapy difficult to tolerate
because of myelosuppression, and that it resulted irt a low
salvage rate and in many patients injury of the small intestine. We are completing a study of the usefulness of radiotherapy in patients whose microscopic residual disease was
discovered at second-look laparotomy after combination
chemotherapy.

Chemotherapy: Some Progress
For most patients with epithelial ovarian cancer, the
postoperative therapy is chemotherapy. Earlier, this
involved single alkylating agents but by the mid-l 970s
changed to combination chemotherapy, when new active
agents such as doxorubicin, hexamethylmelamine, and cisplatin-were-tested in clini-ea-1-tri-a-ls-:-ln the last deca-de, some
critical issues concerning combination chemotherapy have
been at least partially resolved. Although the superiority
of combination chemotherapy over single-agent therapy
is still somewhat controversial, I believe that existing evidence favors the combination. In patients with advanced
ovarian cancer, response rates to combination chemotherapy approximate 50% to 60%, and median survival periods
range from 25 to 32 months. Many clinical trials have yet
to produce mature data, but early results suggest that the
five-year survival rates for patients with advanced disease
treated with the best available combination chemotherapy
are no better than 20% to 25%.

called early ovarian cancer referred to major medical centers, about one-third are found by reexploration or other
types of careful study to have more advanced disease.
Patients who complete initial surgery with minimal resid- ~ual disease (2-Em-er less) have a mueh-greater chance ef-eure---than patients who still have bulky disease after initial surgery. Cytoreductive surgery may, in addition to resection
of the pelvic organs, include radical resection of the omentum, small-intestinal resection in about 10% of patients,
and resection of the rectosigmoid colon in up to 30% of
patients. When normal tissue planes in the pelvis are obliterated by tumor infiltration, a retroperitoneal approach
avoids injuring the ureters and iliac vessels.
Although optimal cytoreductive surgery is possible in
about 75% of patients, conservative surgery, that is, unilateral salpingo-oophorectomy, may be appropriate for young
patients who want to have children and in whom the dis-
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neal cavity requires large volumes of fluid. Second, safe and
effective drug delivery systems were devised, including the
Tenckoff catheter and Port-a-Cath. Yet these technical and
pharmacologic advances do not necessarily translate into
therapeutic advantages. Preliminary results suggest that
intraperitoneal chemoth~rapy may be effective for some
patients whose residual disease is minimal after remission
induction with systemic chemotherapy. We hope that current clinical trials will elucidate the role of intra peritoneal
chemotherapy in patients with minimal residual disease,
the efficacy of multiagent intraperitoneal chemotherapy,
and the role ofintraperitoneal chemotherapy in previously
untreated patients. In the meantime, this treatment
remains experimental.

Along the way, however, therapeutic methods have been
refined in a number of ways. Despite some evidence to the
contrary, most experts agree that cisplatin should be one of
the major components of any combination chemotherapy
regimen for this disease. Furthermore, accumulating evidence shows that two-drug regimens are much less toxic
and just as efficacious as three- and four-drug regimens.
When first introduced, combination chemotherapy was
administered for 12 cycles, or one year. Current information suggests that a maximum of six to nine cycles is best
for these patients. Now we also have much better antiemetic agents, including steroids and metoclopramide.
Current standard postoperative chemotherapy for patients
with epithelial ovarian cancer at UTMDAH includes the
regimen of cisplatin and cyclophosphamide for six cycles,
then second-look laparotomy.

High-Dosage Chemotherapy
High-dosage or intensification chemotherapy to circumvent the problem of multidrug resistance is another area
of exploration. The use of high-dose cisplatin in patients
whom conventional doses of the drug failed to benefit has
been reported. Unfortunately, the ototoxicity and neurotoxicity of this approach has been so prohibitive that we
cannot currently recommend it. As for high doses of alkylating agents in conjunction with autologous bone marrow
rescue, experience is scant. At UTMDAH, we are currently embarking on an intensification chemotherapy protocol combining etoposide, cisplatin, and cyclophosphamide with bone marrow rescue as first-line therapy for
patients with bulky residual epithelial ovarian cancer.
Neurotoxicity is the major dose-limiting problem associated with cisplatin therapy. Considerable research has been
done in the last few years to find an analogue of cisplatin
that will have equivalent activity but less neuro- and nephrotoxicity. A number of reports documented the fact that
the cisplatin analogue carboplatin is associated with much
less renal, auditory, gastrointestinal, and neurological toxicity than cisplatin, but with more myelosuppression. Preliminary results suggested also that the activity of carboplatin is equivalent to that of cisplatin. Perhaps the analogue
will eventually replace cisplatin in combination therapy, although results of further phase III trials will have to be
evaluated with regard to its activity and TDyelotoxicity.
The data so far indicate little non-cross-resistance between
cisplatin and carboplatin.

Intraperitoneal Chemotherapy
Dissatisfied with the ultimate results of combination
chemotherapy, physicians and researchers have undertaken
some new approaches, one of which is a new version of
intraperitoneal chemotherapy. This method has been used
in treatment of ovarian cancer since the 1950s but lost popularity as newer, more effective systemic chemotherapeutic
agents were discovered. Intraperitoneal chemotherapy has
several hypothetical advantages: (1) ovarian cancer is primarily confined to the peritoneal cavity; (2) most active
agents against ovarian cancer can be safely infused into the
peritoneal cavity; and (3) whereas the method achieves a
drug concentration in the peritoneal cavity much higher
than is achieved by systemic administration, drug levels in
the systemic circulation are equal or lower, thereby allowing for free-surface diffusion of the drug as well as capillary
flow. Indeed, there is now ample evidence that very high
drug concentrations can be achieved in the peritoneal cavity along with acceptable systemic toxicity.
The rebirth of intra peritoneal chemotherapy was accompanied by two major advances in drug delivery. First, we
now know that uniform distribution of drug in the perito-

Biologic Response Modifiers
Among other interesting experimental approaches is
therapy with such biologic response modifiers as the interferons, recombinant interleukin 2 (IL 2) and lymphokineactivated killer (LAK) cells, and monoclonal antibodies.
Preliminary data from phase I and II trials suggested that
continued on page 8
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Hematopoiesis in Myelodysplastic Syndromes Improves
with Granulocyte-Macrophage Colony-Stimulating Factor
by Saroj Vadhan-Raj, M.D.
Department of Clinical I mmunowgy and Biowgical Therapy

Table I
The myelodysplastic syndromes, a group of stem-cell
disorders arising from cell maturation defects, are characterized by defective hematopoiesis in all marrow cell lineages,
refractory cytopenias, functional abnormalities of mature
cells, and a substantial risk of
leukemic transformation.
Saroj Vadhan-Raj
Most patients affected by these
disorders are elderly, and many succumb to complications
related to bone marrow failure whether the defect evolves
into acute leukemia or not.
Providing effective treatment for these disorders remains
a difficult problem. Most attempts to stimulate hematopoiesis with androgen hormones, steroids, and hematinic
agents have been unsuccessful. Several differentiationinducing agents including retinoids, vitamin D, and low
doses of cytarabine have been used to treat these patients,
with disappointing results. Toxicity has been high, the
response rate low, and the survival rate not significantly
higher. Palliative therapy with blood products has therefore been an essential ingredient of treatment for this
disease.
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a T cell-derived lymphokine with a broad
range of biologic activities. The rationale for using GMCSF in treating patients for myelodysplastic syndromes is
that it stimulates hemopoietic progenitor cells to proliferate and differentiate, and it enhances the functional activities of mature cells such as neutrophils, monocytes, and
eosinophils.
The recent cloning of the gene for human GM-CSF made
it possible to assess the role ofGM-CSF in therapy for myelodysplastic syndromes. As part of a broad phase I study of
patients with cancer or bone marrow failure, or both, we
administered recombinant human GM-CSF to eight patients who had myelodysplastic syndrome. The objectives
were to stimulate hematopoiesis in these patients, improve
their blood counts, and thus reduce their risk of infection
and hemorrhage. The treatment was administered by continuous intravenous infusion daily for two weeks. After a
two-week rest period, the treatment cycle was repeated.

CHARACTERISTICS OF PATIENTS
Median age (range)
Median physical status (range)
Men/women

66 (43-79)
70 (60-90)
6/2

FAB Classification
RA
RAEB
RAEB-T

3
4

Karyotypic abnormality
Previous chemotherapy
Other malignant condition
Poncytopenia

5/8
5/8
4/ 8
7/8

Transfusion requirements
Red cells
Platelets

8/ 8
4/8

FAB, French-American-British Cooperative Group Classification
RA, refractory anemia
RAEB, refractory anemia with excess blasts
RAEB-T, RAEB in transformation

Clinical Characteristics
Most of the patients we studied (Table 1) were advanced
in age and had a poor prognosis because of excess blasts in
bone marrow, chromosomal abnormality, previous exposure to chemotherapy, and the presence of other malignant
conditions. Although preleukemic syndrome lasts a highly
variable period of time, the presence of cytogenetic abnormalities and records of previous exposure to mutagens portended poor prognoses for these patients, including shorter
survival and a higher likelihood that the disease would progress to acute leukemia. Furthermore, as the data in Table 1
show, seven of our eight patients had pancytopenia, four
patients required platelet transfusions, and all needed redcell transfusions before the GM-CSF treatment.
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Hematologic Response to GM-CSF Treatment

38,------------,
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In all patients the treatment was associated with marked
increases in white blood-cell and granulocyte counts
(Figure 1). The elevation in white counts seemed to be
dose-dependent, with increases up to 30,000/mm 3 at lower
doses (120 µg/m 2 or less) and up to 100,000/mm 3 at higher
doses (250 µg/m 2 or more) . Although increases in neutrophilic granulocytes were the predominant response, significant increases were observed also in eosinophils, monocytes,
and lymphocytes.
In addition to a rise in white blood cells, three of the
eight patients experienced multilineage responses characterized by two- to tenfold increases in platelet counts and
responses in red cells that freed two of the three patients
from red-cell and platelet transfusions for 20 and 40 weeks,
respectively.
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Figure 2. Effects of treatment with recombinant human granulocyte-macrophage colonystimulating factor on hematologic parameters in a patient with myelodyplastic syndrome .
A, effects on leukocyte ( ■ ), granulocyte ( • ), and platelet (A) counts . B, effects on
corrected reticulocyte count, hematocrit, and transfusion requirements (arrows) . From S.
Vadhan-Raj, M. Keating, A. Le Maistre, et al. New England Journal of Medicine
1987 ;317: 1548. Reprinted with permission.
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bone marrow function and increased his blood counts; the
increase in granulocyte rendered him free of infections.
This is the patient who did not require red-cell and platelet
transfusions for more than 40 weeks.
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Reasons for Response
We were interested in understanding the biologic basis for
these patients' response. The rapid increase in white cells,
for example, suggested that the response begins with the
release of mature cells from the bone marrow. The fact that
the white-count elevation was sustained (Figure 2) indicated the second component of the response to be at the
stem-cell level. Our observations of a higher number of
bone-marrow stem cells in the proliferative cycle and of
increased bone-marrow cellularity after GM-CSF treatment support this notion. These findings also explain why
in some patients the baseline granulocyte counts improved
with repeated treatment cycles.
In treating patients for myelodysplastic syndromes, the
ultimate goal is to prevent evolution of the disease in acute
leukemia and to restore the patients' normal hematopoiesis. Because 15% to 40% of these patients develop acute
leukemia, treatment with antileukemic agents seems a logical approach. Yet, even at low dosages, these agents are
often poorly tolerated because the patients have low bonemarrow reserve and profound cytopenias. One intriguing
approach, therefore, would be to eradicate the abnormal

Figure l . Effects of treatment with increasing doses of recombinant human granulocytemacrophage colony-stimulating factor on white blood cells and granulocytes (striped area)
in patients with myelodysplastic syndromes.

Other Clinical Benefits
Among the clinical benefits was a reduced rate of infection. In the three months preceding GM-CSF treatment,
five patients had had 12 febrile episodes for which they
required intravenously administered antibiotics. While in
this study, in contrast, three patients required antibiotic
treatment on three occasions. Furthermore, three patients
previously considered poor risks for surgery grew healthy
enough to undergo operations for their underlying
illnesses.
Figure 2 shows the hematologic benefits ofGM-CSF
treatment in a patient who had had hypoplastic bone marrow for three months after low-dose chemotherapy. During this period the patient had required frequent red-cell
and platelet transfusions and antibiotics for recurrent infections. Treatment with GM-CSF improved the patient's

continued on page 8
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The Psychosocial Impact of Cancer
and the Role of Social Work
by Kathryn F. Kennedy, M.S. W., C.S. W. and
Wayne L. Dorris, Ph.D., C.S.W.-A.C.P.
Research and Education, Department ofSocial Work

Kathryn F. Kennedy

services, in fact, involves counseling patients and family
members. Much of this interaction focuses on questions
of treatment effectiveness and the influence extended
treatment programs have on the patients' and family
members' lives.
These patients are concerned about their relationships
with others, are afraid oflosing independence and career
opportunities, and have sorrows about the integrity of
their bodies and physical functions. They fear death. So it
is not surprising that 20% of hospitalized cancer patients
experience significant emotional distress. The social workers' involvement in providing emotional support for patients and families, together with assistance in solving
concrete problems (finances, housing, transportation,
employment, medical equipment, and the myriad of
arrangements that need to be made for home health care,
hospice, or nursing home placement) are therefore an
essential part of medical care at our hospital.

Wayne L. Dorris

No disease diagnosis arouses as much fear and dread as cancer, which one of three Americans experiences directly and
which causes almost 450,000 deaths a year. Hearing this
diagnosis, a person's first response may be a feeling of acute
emotional turmoil, of shock and disbelief. Anxiety and
depression often follow, but these may abate as the patient
begins to accept the information and to participate actively
in his or her treatment. The next challenge is coming to
grips with issues that concern the threat of recurrence after
treatment and the possibility of diminished life span. These
worries are realistic. Most patients struggle with them, and
unless recognized and acknowledged, they may interfere
with the patient's compliance and response to treatment.
At the same time, differences in symptomatology, personality, age, social status, and support systems inevitably
make each patient's reactions unique. No patient's case is
typical, and each has its own agonies and ironies. Because
age makes a crucial difference, we pay attention to when in
the patient's life cycle the disease has occurred. Older people who may have cancer at more advanced stages tend to
experience deeper depression than younger patients, whereas
younger ones may express more resentment and be less
cooperative as an expression of their anger.

Identifying the Profoundly Troubled Patient
Early identification of the individuals who are likely not
to cope well with their illness and treatment is essential to
treatment planning. These patients have often had difficulties in handling other crises in their lives. The unusually
troubled patient may generally be identified by symptoms
of anxiety and agitation, unrealistic perception of the illness, and extreme behavior. Feelings of worthlessness and
guilt are particularly sharp indicators of potential emotional crises. Profoundly upset, such a patient may express
suicidal thoughts. The social work practitioner will focus
on the patient's support system of family, friends, religious, and work groups to encourage continuing contact
and support. Besides simply being available when needed,
social workers may help to provide transportation and
financial assistance. Without this support, troubled patients may become isolated, withdrawn, noncompliant
with treatment, and unable to mobilize enough energy
and determination to fight their disease.

Deal with Sexual Problems Early
Fears and misunderstandings about cancer may also lead
to impotence and frigidity. Whether a patient's sexual
impairment is organic or psychological, both patient and
partner should participate in counseling early in the treatment process. ~uch a problem can often be identified and
dealt with successfully before it becomes integrated into
the patient's lifestyle and accepted as a normal byproduct
of cancer and its treatment.

We See 1,500 Patients Monthly
At UT M. D. Anderson Hospital and Tumor Institute,
we in the Department of Social Work see an average of
1,500 patients a month. More than one-fourth of these
patients need counseling because they have difficulty adjusting to their illness. More than 60% of our social work
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Emotional Support
By virtue of their relationship, family members play two
distinct and potentially contradictory roles in the patient's
treatment and recovery process. They function as the patient's first line of emotional support and are so perceived
and encouraged by health professionals. Simultaneously,
health professionals view them as equally in need of attention and support, and varying in ·ability to cope with the
impact of a cancer diagnosis.
Both patients' and relatives' scores on various questionnaires and tests have been found to be significantly correlated with the patients' medical condition. Stress and anxiety scales related to cancer diagnosis and administered to
patients and families reveal equally elevated scores-often as
much as twice as high as those of the general population.
Understanding this interrelationship is of fundamental
importance in caring for patients with cancer. A supportive family environment is believed to enhance the capacity
to adapt to illness and treatment.
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Toughest Problems

Cancer patients find it particularly hard to cope with
pain, manage uncertainty, modify the reality of their lives,
and redefine time. Chronic, unrelenting pain is the most
disturbing-a private experience no machine or instrument
can quantify. At M. D . Anderson Hospital, the Pain Service provides specialized treatment when this becomes a
significant and u nresolved problem.
Because survival rates vary widely for the various types of
cancer, a growing number of men and women in our country now live with cancer and the uncertainty of recurrence.
Mobilizing emotional and financial resources to fight this
As cancer has become more treatable and more patients surdisease over months and years is difficult for most people.
vive the illness longer, quality oflife and total care have
Suddenly the patients' lives are redefined in terms of treatbecome central issues . To lessen patients' uncertainty
ments and remissions. Rather than plan several years in
about their illness, physicians now commonly explain the
advance, patients must focus on living day-to-day, weeknature of the illness to patients, describing findings, treatto-week; the uncertainty is with them constantly, as may
ment, and prognosis. This contrasts sharply with prevalent
be their pain and discomfort. The world of patients,
attitudes 20 years ago, when 90% of doctors reported in a
revolving around the medical system and its time frame,
1961 survey that they did not tell cancer patients their
takes on a different meaning and dimension. Time is very
diagnosis. Our current beliefis that the more patients
different in this new reality of cancer and cancer treatment.
know and understand, the more certain and secure will
A comprehensive approach to cancer care requires, therethey feel.
fore, awareness and consideration of the psychosocial facOnce diagnosed, cancer becomes a part of these patients'
tors associated with the illness. At our hospital, we are for- ~1i~v~es~,- fico~r~c~m~g~tth=e=m~t=o~a~1=te=r~th~e~1~r~s~e=n~se~ o~f~r-e-a~h~ty~b-e_c_a_u_se- - - -~tu~n-atbe~t~hheksr~~-sefr~W&k-- - the disease changes family relationships, puts friendships
ratios in Texas, so the team approach is an essential part of
on trial, and may even cost a patient his or her job. The
care and reflects this reality. Increasing recognition of these
patient's ultimate balancing of the realistic or unrealistic
psychosocial factors is reflected by patients' improved treatfears associated with cancer diagnosis and adjustment to the
ment compliance, their enhanced responsiveness to treatpsychosocial stress of the treatment process itself depends
ment, and an improvement in the quality of their lives. ■
on many of the factors discusse~. Those who make a good
adjustment demonstrate resilience, adaptability, and
Physicians who desire additional information may write Kathryn F.
resourcefulness under severely difficult circumstances, a
Kennedy, M.S.W., C.S.W., or Wayne L. Dorris, Ph.D., C.S.W.-A.C.P.,
self-contained capacity to cope with problems, and the
Department of Social Work, Box 103, The University of Texas M. D.
supportive and enhancing effects of patient-family-friends
Anderson Hospital and Tumor Institute at Houston, 1515 Holcombe
Boulevard, Houston, Texas 77030, or call (713) 792-7139.
relationships.
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Epithelial Ovarian Cancer continued from page 3

Myelodysplastic Syndromes continued trom page s

intraperitoneally administered interferon and intraperitoneal or systemic IL 2 with LAK cells achieve anti tumor
activity in ovarian cancer patients. Several clinical trials of
these agents as well as of monoclonal antibodies linked to
drugs, toxins, or radionuclides are under way; results
should become available in the next few years.

clones with chemoth rap and then timulate normal elements with GM-CSF. A i illu trated b t h lini al ur e
of one such patient (Figure 2) GM- F migh t b ffe ti, c
in restoring normal h mat p ie i in pati nt r nd red
hypoplastic b chem therap .
The patient who
r tr at d a utpati n t t 1 rated
the therap well. Th 6
id f6 t th
d
included flulike mptom and b n pain .
Our findings d moo trat d that GM t im ulat
hematopoi si significant! in hum n . TI atm nt ith thi
hormone ma benefit pati nt ith m 1 d pla t i
ndromes and c topenia b impro ing bl d 1 m nt and
thus reducing the morbidit r lated to in ti ti n h m rrhages and transfusions. The long-t rm impa t f GMCSF treatment on th natural hi tor of m 1 d pla t i
syndromes, including its effect on leukemic tran form at ion
and survival, needs to be learned from controll d clinical

Hope for N ext Decade
Our hope for the next 10 years or so is that innovative
methods like intraperitoneal chemotherapy, intensification
chemotherapy, and multimodality therapy will raise our
patients' survival rates. Therapy with biologic response modifiers, although in its infancy, will also be studied carefully and will, we hope, assume its proper role in the armamentarium against epithelial ovarian cancer. Meanwhile
the search continues for more active agents against this disease. The ultimate hope lies in the early detection of ovarian cancer with a reliable serum tumor marker. ■

studies. ■

Physicians who desire additional information may write David M .
Gershenson , M.D ., Department of Gynecology, Box 67, The University
ofTexas M . D . Anderson Hospital and Tumor Institute at Houston ,
1515 Holcombe Boulevard , Houston , Texas 77030, or call
(713) 792-2770.

Physicians who desire additional information ma , rite Saroj adhan-Raj
M.D. Department of Clinical Immunology and Biological Therapy Box
41 The University ofTexas M . D . Anderson H o pita! and Tumor In titute
at Houston , 1515 Holcombe Boule ard Hou ton Texa
030 or call
(713) 792-7966.

8

